Tacrolimus is an immunosuppressant commonly used in the prevention of graft-versus-host disease (GVHD) following allogeneic HCT. Unfortunately, the use of tacrolimus is associated with variable immunosuppression and toxicity. The purpose of this study was to describe tacrolimus population pharmacokinetic parameters, to identify relationships between clinical covariates and pharmacokinetic estimates, and to develop a model to predict tacrolimus clearance in HCT patients. Steadystate whole blood tacrolimus concentrations (n = 1625) obtained during intravenous and oral therapy were analyzed in 122 patients. Population clearance (CL) was 5.22 l/h and bioavailability (F) was 0.28. The influence of clinical covariates on population estimates of CL and F of tacrolimus were tested with nonlinear mixed effects models (NONMEM). CL was significantly reduced by elevations in total bilirubin 2.0-9.9 mg/dl (CL Ɇ 0.797), bilirubin у10 mg/dl (CL Ɇ 0.581), serum creatinine у2 mg/dl (CL Ɇ 0.587), grade III/IV graft-versus-host disease (CL Ɇ 0.814) and veno-occlusive disease (CL 0.814). No covariates were predictive of oral F. The interindividual variabilities in CL and F were 33% and 44%, respectively. Residual variability was 27.5% and 16.8% at tacrolimus concentrations of 10 g/l and 20 g/l, respectively. These models may be used to predict tacrolimus clearance and doses in adult patients following HCT. graft-versus-host disease (GVHD), are barriers to successful transplantation. Optimal pharmacologic immunosuppression is critical in reducing the risk of GVHD. Tacrolimus has been investigated as an alternative to cyclosporine for the prevention of GVHD following HCT.
graft-versus-host disease (GVHD), are barriers to successful transplantation. Optimal pharmacologic immunosuppression is critical in reducing the risk of GVHD. Tacrolimus has been investigated as an alternative to cyclosporine for the prevention of GVHD following HCT. [1] [2] [3] [4] [5] [6] [7] Randomized clinical trials comparing tacrolimus with cyclosporine showed that a tacrolimus/methotrexate regimen is superior to cyclosporine/methotrexate in preventing GVHD. 6, 8 The pharmacokinetics of tacrolimus are well described in patients undergoing solid organ transplantation, 9, 10 however, they have been evaluated in only small numbers of HCT patients. 2, 11, 12 Unfortunately, pharmacokinetic data from the solid organ setting poorly represent the pharmacokinetic disposition of tacrolimus in patients undergoing HCT. HCT patients receive lower doses of tacrolimus, receive long courses of intravenous therapy and develop chemotherapy-related complications including mucositis, renal dysfunction, veno-occlusive disease (VOD) and GVHD of the gastrointestinal tract and/or liver. These factors may alter the bioavailability and clearance of tacrolimus.
Nephrotoxicity and neurotoxicity secondary to tacrolimus therapy is prevalent following HCT 13 and is associated with tacrolimus blood concentrations Ͼ20 ng/ml. 14, 15 Nephrotoxicity (SCr Ͼ2.0 mg/dl) occurs in 32-92.6% of patients undergoing related or unrelated donor HCT. [2] [3] [4] [5] 7, 13, 16 In one study, the risk of developing nephrotoxicity (SCr Ͼ2 mg/dl) was increased by 84.4% when the mean tacrolimus concentration was Ͼ20 ng/ml.
14 Neurotoxicity ranging from mild tremors and paresthesia to severe manifestations such as cortical blindness and seizures are also well described following HCT. 3, 13, [17] [18] [19] [20] [21] These toxicities underscore the need for vigilant monitoring of tacrolimus blood concentrations and accurate dose modifications.
The objective of this study was to determine the population pharmacokinetic parameters of intravenous and oral tacrolimus in the first 4 months post transplant, and to evaluate relevant clinical covariates for their effects on tacrolimus clearance and bioavailability.
Patients and methods

Study population
Data were retrospectively obtained from the medical records and the Blood and Marrow Stem Cell Transplant Program database at the University of Michigan. Data in 122 patients undergoing HLA-matched sibling or unrelated donor HCT for hematologic malignancies were included in this evaluation.
GVHD prophylaxis
All patients received intravenous tacrolimus, 0.03 mg/kg/ day by continuous infusion beginning on the day prior to allogeneic transplantation. Oral tacrolimus was substituted at four times the intravenous dose in two divided doses per day when tolerated. Full dose tacrolimus therapy was continued until day 56 at which time a taper was begun at 20% every 4 weeks and discontinued on day 181. Methotrexate (10-15 mg/m 2 ) was given in conjunction with tacrolimus on days 1, 3, 6 and 11 post transplant for GVHD prophylaxis in patients who received related or unrelated donor marrow stem cells. Patients who received related peripheral blood donor stem cells did not receive methotrexate.
Tacrolimus blood concentrations
Tacrolimus whole blood steady-state concentrations were measured two or three times weekly during continuous intravenous infusion. Trough concentrations were measured one or two times weekly during oral therapy. Patients with tacrolimus toxicity or tacrolimus dosage changes received more frequent monitoring. Tacrolimus whole blood concentrations were obtained as long as clinically indicated, until time of relapse, death, discontinuation of tacrolimus or until day 120. Only whole blood concentrations obtained at steady state were used in this analysis. Steady-state was defined as at least 48 h of the same dose and route of tacrolimus following the initiation of therapy or change in dose.
Tacrolimus was held or the dose was modified based on the whole blood concentration, serum creatinine, total bilirubin and neurotoxicity. The targeted whole blood concentrations were initially 10-30 ng/ml, but later reduced to 10-20 ng/ml. Whole blood concentrations were measured with the Abbott ImX analysis method with a detection limit of 5 ng/ml. 22 Any values reported as Ͻ5 ng/ml were omitted from the analysis.
Data collection
Baseline patient characteristic data collected were age, recipient and donor gender, type of hematologic malignancy, transplant type, preparative regimen, HLA match/mismatch, total body weight on admission, baseline serum creatinine and the number of administered methotrexate doses. Additional data were recorded with each tacrolimus whole blood concentration: tacrolimus dose and route of administration, day post transplant, SCr, total bilirubin, VOD and GVHD.
Diagnosis of GVHD and VOD
The day of onset and grade of acute GVHD was recorded until day 100. GVHD was diagnosed and graded according to standard clinical and pathological characteristics. 23 Skin, gut and liver biopsies were obtained as clinically indicated. All GVHD diagnoses were evaluated and scored by a senior attending physician. VOD was diagnosed clinically in the presence of hyperbilirubinemia, ascites and hepatomegaly.
Population pharmacokinetic modeling
A nonlinear mixed effects model (NONMEM), version V, level 1.0, 24 with double precision analysis installed on a Gateway Pentium III computer located in the Biomedical Modeling Laboratory at the University of Minnesota, College of Pharmacy was used for this analysis. Tacrolimus blood concentrations from all subjects were simultaneously analyzed to obtain the population parameters of interest. Results were expressed as a mean pharmacokinetic parameter population estimate and its variance. Clinical covariates associated with changes in the pharmacokinetic parameter population estimates were identified. Steadystate concentrations obtained during continuous intravenous infusion and oral therapies were analyzed. Clearance and bioavailability were obtained; volume of distribution and elimination rates could not be estimated. During intravenous infusion, the average steady-state blood concentration (Css) was modeled as:
where R o (mg/h) was the infusion rate of tacrolimus and CL (l/h) was the clearance. Following oral dosing, the average steady-state concentration over a dosing interval was modeled as:
where CL was as in equation 1 and D was the dose in mg. Tau () was the dosing interval in hours and F was the oral bioavailability. In our study, steady-state trough concentrations during oral administration were assumed to approximate the average steady-state concentration. In the case of long half-life drugs (eg tacrolimus, cyclosporine, phenytoin, digoxin), the average steady-state concentration generally approximates the steady-state trough concentration. However, because trough concentrations may be slightly less than average steady-state concentrations, our estimated bioavailability may be slightly less than the actual bioavailability.
Interindividual variability in CL and F were modeled as log-normal distributions. Residual variability was characterized by a combined proportional and additive model that allowed the residual error to increase with the value of the predicted concentration, but not in a strictly proportional way.
Development of the regression model
A forward inclusion and backward elimination approach was used to build a regression model for CL and F. The influence of total body weight (as a continuous variable), age (Ͻ21 years, 21 to 50 years and Ͼ50 years), donor or recipient gender (male vs female), type of hematologic malignancy (AML, CML, ALL, lymphoma, MM and others), HLA typing (6/6 vs 5/6), preparative regimen (BAC, BACT, BU/CY, BU/CY/TMI, CBV and other), number of doses of methotrexate (0 to 4), transplant types (unrelated vs related), SCr (Ͻ2 mg/dl and у2 mg/dl), total bilirubin (Ͻ2 mg/dl, 2-9.9 mg/dl, у10 mg/dl), grade of GVHD (0 to 4), VOD (presence or absence), and days post transplant on CL and F of tacrolimus were tested.
During forward inclusion, a change in objective function of greater than 6.6 in testing a single covariate was significant ( 2 , df = 1, P = 0.01). All covariates producing a significant reduction in the objective function were used to construct the full regression model. During backward elimination, each covariate was eliminated individually from the full regression model to confirm its significance. If the objective function increased by 6.6, removal of the covariate was considered to produce a significantly inferior model ( 2 , df = 1, P = 0.01). A final model was constructed with all covariates that were significant during forward inclusion and backward elimination.
Results
Patient characteristics are summarized in Table 1 . We obtained 1819 tacrolimus whole blood concentrations in 122 subjects (117 adults and five adolescents). Tacrolimus concentrations were excluded from the pharmacokinetic analysis if not obtained at steady state (n = 33), obtained while tacrolimus was temporarily withheld (n = 91), or if a concentration was below the level of assay quantification (Ͻ5 ng/ml) (n = 70). The final data set consisted of 1625 tacrolimus blood concentrations; 701 during intravenous and 924 during oral therapy. A median of 13 (range 2-28) 
Regression analysis
Several clinical covariates resulted in a reduction in tacrolimus clearance; SCr у2 mg/dl, total bilirubin 2-9.9 mg/dl, total bilirubin у10 mg/dl, presence of grade III or IV GVHD and the presence of or a previous diagnosis of VOD. During forward inclusion, receiving a fourth dose of methotrexate significantly increased clearance and decreased bioavailability of tacrolimus, but its effect was minimal during backward elimination. Similarly, bioavailability was improved у30 days post transplant with forward inclusion; however, its effect was minimal during backward elimination. In the final model, no significant clinical covariates were found to be predictive of bioavailability.
The pharmacokinetic parameter population estimate for tacrolimus clearance and oral bioavailability were 5.22 l/h and 0.28, respectively ( Table 2) . The final regression model for the prediction of CL using the significant covariates in an individual patient was: CL (l/h) = 5.22 l/h (population estimate of clearance) × applicable patient-specific covariates. Patient-specific covariates were 0.797 if total bilirubin is between 2 and 9.9 mg/dl; 0.581 if total bilirubin у10 mg/dl; 0.587 if SCr у2 mg/dl; 0.814 if grade III-IV GVHD present; and 0.814 if VOD present or previously diagnosed.
In modeling interindividual variabilities, the square root of the variance is interpreted as the coefficient of variation. The variability of CL was estimated to be 33.0% and that of bioavailability was 44.3%. The residual variability model used allowed a larger relative error at lower concentrations than at higher concentrations. At a tacrolimus concentration of 10 g/l, the variability was 27.5%, whereas at a concentration of 20 g/l, the variability was 16.8%.
Discussion
This is the first report of tacrolimus population pharmacokinetics and the largest pharmacokinetic evaluation in HCT.
We found a tacrolimus pharmacokinetic population estimate of clearance of 5.22 l/h (ie approximately 0.075 l/h/kg in a 70-kg adult) in 117 adult and five adolescent HCT patients. This is similar to clearance estimates (0.055-0.075 l/h/kg) reported following intravenous tacrolimus to 31 adult HCT patients. 11 Tacrolimus pharmacokinetics were also evaluated in seven children (8 to 17 years of age). 12 Mean initial clearance/kg of body weight during intravenous therapy was higher, 0.108 (range 0.079-0.142) l/h/kg than adult patients. Recently, intravenous tacrolimus clearance estimated from concentrations obtained during routine clinical care was reported in 55 children (6 months-18 years of age). 25 Mean clearance in children Ͻ6, 6-12 and Ͼ12 years of age was 0.159 ± 0.082, 0.109 ± 0.053 and 0.104 ± 0.068 l/h/kg, respectively. The above reported clearance values are highly variable. It is difficult to apply these findings in clinical practice since these clearance estimates do not identify the covariates responsible for the observed variability. In our study, we estimated pharmacokinetic parameters in conjunction with common clinical covariates to build a model to predict individual tacrolimus clearance that may be used in the clinical setting to estimate dose requirements.
We determined the pharmacokinetic parameter population estimate for tacrolimus clearance and identified four clinical covariates (elevated bilirubin, SCr, GVHD and VOD) that are strongly correlated with clearance. Tacrolimus is primarily metabolized in the liver and intestinal mucosa by the cytochrome P4503A4 enzyme, and eliminated through biliary excretion.
9,26-29 Therefore, clinical events, which impair hepatic function, may reduce tacrolimus clearance. We found that moderate rises in total bilirubin (2-9.9 mg/dl) resulted in approximately 20% reduction (change in population CL estimate of 0.797) in the population pharmacokinetic clearance estimate. A total bilirubin, у10 mg/dl, resulted in approximately 40% reduction (change in population CL estimate of 0.581) in the population pharmacokinetic clearance estimate. This is consistent with our clinical observations in patients with elevated total bilirubin. In addition, others have reported marked reductions in tacrolimus clearance in seven children with deteriorating liver function. 12 We also found that a rise in SCr у2 mg/dl was independently associated with a 40% reduction in tacrolimus clearance (change in population CL estimate of 0.587). Tacrolimus undergoes almost no renal elimination, therefore the association between tacrolimus clearance and SCr is unclear. 9, 10 We hypothesize that a high SCr may serve as a surrogate of altered renal blood flow resulting from subclinical hepatic injury.
GVHD (grade III-IV) or VOD moderately decreased tacrolimus clearance (change in population CL estimate by 0.814). GVHD resulted in clearance changes independent of total bilirubin; therefore, GVHD in itself, reduced tacrolimus clearance. In addition, VOD resulted in an approximate 20% reduction (change in population CL estimate of 0.814) in tacrolimus clearance. VOD is a result of direct hepatocyte injury; therefore, reductions in hepatic clearance are expected.
We found a tacrolimus oral bioavailability of 28%, suggesting a 1:3.5 intravenous to oral conversion ratio. This finding is consistent with clinical practice, where a 1:3 or 1:4 conversion is used. We did not find significant clinical covariates that predicted oral bioavailability. In forward inclusion analysis, patients receiving the fourth dose of methotrexate, or were Ͻ30 days post transplant, had lower bioavailability; however, it was not significant with backward elimination. Early pharmacokinetic studies found that patients receiving methotrexate and tacrolimus had lower bioavailability (16%) than those receiving tacrolimus monotherapy (49%). 3 The authors hypothesized that methotrexate worsened preparative regimen-related mucositis of the gastrointestinal tract, resulting in poorer absorption. In our study, all patients initially received intravenous tacrolimus and were converted to oral therapy after they were able to tolerate oral food intake. Most patients were converted to oral tacrolimus between weeks 2 and 4 post transplant; therefore, it is possible that their mucositis had sufficiently healed and the full extent to which methotrexate reduced bioavailability was not detectable.
We did not find a relationship between age, body weight, or preparative regimen, and tacrolimus clearance. Pediatric patients generally have a higher weight-normalized clearance than adults, 12 therefore, weight is usually associated with clearance. 11 Although we did not observe this association it does not exclude its effect since only five adolescents and no pediatric patients were analyzed.
The following example illustrates how the regression model for clearance may be used in the clinical setting: A 70 kg adult with a total bilirubin of 11 mg/dl, SCr of 2.3 mg/dl, and grade III GVHD will have an estimated tacrolimus clearance of: CL (l/h) = population clearance estimate × applicable patient-specific covariates; CL (l/h) = 5.22 × 0.581 × 0.587 × 0.814 = 1.45.
Once the approximate tacrolimus clearance of an individual is known, an estimate of the dose needed to achieve a desired whole blood concentration is possible using the following equation. For example, if the desired concentration is 15 g/l (0.015 mg/l), the predicted daily intravenous dose (mg/day) is: Desired concentration (mg/l) × estimated CL (l/h) × 24 (h/day) = 0.015 × 1.45 × 24 = 0.522 mg/day intravenously. If oral dosing is desired, population F = 0.28 (28%) and total daily oral dose (mg/day) is: i.v. dose in mg/day/F = 0.522/0.28= 1.9 mg/day divided in two oral doses.
Five assumptions were made for the purposes of this study. The first assumption was that all tacrolimus concentrations were obtained at steady-state. Steady-state was defined as at least 48 h of unchanged and properly timed dosing. With a half-life of approximately 12-18 h, tacrolimus concentrations would be about 85% of the actual steady-state concentrations within 48 h. Given the narrow therapeutic window of tacrolimus, achieving complete steady-state prior to performing therapeutic drug monitoring is often not feasible clinically. Second, we modeled our trough steady-state concentrations during oral administration as average steady-state concentrations. Tacrolimus has a relatively long half-life (approximately 12-18 h in HCT), and the assumption that the average steady-state concentrations are approximately equal to the trough steady-state concentrations is reasonable. This assumption has been applied successfully in the therapeutic drug monitoring of oral phenytoin. In patients with a rapid clearance and a shorter half-life, this assumption may not be appropriate, and caution is warranted. The third assumption was that even though tacrolimus concentrations were measured by IMx analysis (which may cross-react with tacrolimus metabolites), the effect on the bioavailability estimate was minimal. Whole blood samples obtained from kidney transplant patients were evaluated for tacrolimus concentrations by nonspecific assays (IMx and ELISA) and by a specific assay (liquid chromatography with mass spectroscopy). Values determined were nearly identical and highly correlated (r 2 = 0.985). 30 The cross-reactivity of five tacrolimus metabolites was also evaluated. 31 Two of the five metabolites showed cross-reactivity with IMx analysis. Their contributions to the final tacrolimus concentration were only 6-14%. The fourth assumption was that patient compliance was achieved. To maximize patient compliance, each patient discharged from the hospital was given an individual medication calendar containing their medications and their respective doses and administration times. These calendars were updated as needed during regular follow-up ambulatory visits. In addition, nurses and clinical pharmacists in the clinic regularly counselled patients regarding their medications. Although these patients are generally highly motivated to take their medications correctly, it cannot be completely assured. The fifth assumption was that the effect of drug interactions was minimal. We lack the information regarding concurrent medications on our patients. HCT patients receive multiple agents that are known inhibitors or inducers of cytochrome P450 3A4 including anti-emetics, corticosteroids, antibiotics and antifungals. Tacrolimus clearance may be over-or underestimated when these agents are combined with tacrolimus. In our study, all patients were treated with the same supportive care regimens representing a stable background. However, supportive care regimens vary between transplant centers and the use of other P450 3A4 inducers or inhibitors may change pharmacokinetic estimates.
In conclusion, understanding tacrolimus pharmacokinetics and the clinical events that lead to alterations in clearance is critical. Tacrolimus concentrations falling outside the therapeutic range may result in toxicity or therapeutic failures; therefore, rapid adjustment of doses is imperative. Further prospective trials using this mathematical model to optimize dosing regimens of tacrolimus is warranted.
